Navegar por autor "Quintero Aldana, Guillermo"

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

2011- Reboredo Lopez, Margarita; Candamio Folgar, Sonia; López López, Rafael; Quintero Aldana, Guillermo; Salgado Fernández, Mercedes; [et al.]

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of KRAS wild-type metastatic colorectal cancer: Final results of a phase II open-label clinical trial

2013- Quintero Aldana, Guillermo; Salgado Fernández, Mercedes

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

2014- Quintero Aldana, Guillermo; Salgado Fernández, Mercedes

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

2013- Candamio Folgar, Sonia; Gallardo Martín , Maria Elena; Campos Balea, Begoña; Álvarez Gómez, Elena; Quintero Aldana, Guillermo; [et al.]

Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: A retrospective analysis

2012- Quintero Aldana, Guillermo; Salgado Fernández, Mercedes

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

2019- Martinez Lago, Nieves Purificacion; Carmona Campos, Marta; Gonzalez Villarroel, P; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz; [et al.]

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; Covela Rúa, Marta; De La Cámara Gómez, Juan Cruz; González Villaroel, Paula; [et al.]

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ?3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

2020- Aranda, Enrique; Viéitez, Jose Maria; Gómez-España, Auxiliadora; Gil Calle, Silvia; Salud-Salvia, Antonieta; [et al.]

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

2013- Valladares Ayerbes, Manuel; Reboredo Lopez, Margarita; Fernández Montes, Ana; Varela Ferreiro, Silvia; Quintero Aldana, Guillermo; [et al.]

Maintenance treatment with cetuximab in a series of patients treated with standard chemotherapy and cetuximab in metastatic colorectal cancer

2011- Vázquez Estévez, Sergio; Varela Ferreiro, Silvia; Campos Balea, Begoña; Quintero Aldana, Guillermo; Mel Lorenzo, José Ramón; [et al.]

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

2015- Gallardo Martín , Maria Elena; Fernández Montes, Ana; Varela Ferreiro, Silvia; Campos Balea, Begoña; Álvarez Gómez, Elena; [et al.]

Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)

2013- Reboredo Lopez, Margarita; Candamio Folgar, Sonia; López López, Rafael; Quintero Aldana, Guillermo; Salgado Fernández, Mercedes; [et al.]

Sorafenib (SOR) in advanced non-small cell lung cancer (NSCLC): A phase II study of patient progress after several lines of treatment

2012- Vázquez Estévez, Sergio; Varela Ferreiro, Silvia; Campos Balea, Begoña; Álvarez Gómez, Elena; Quintero Aldana, Guillermo; [et al.]

Repositorio digital RUNA

Navegar por autor "Quintero Aldana, Guillermo"

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV) ﻿

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of KRAS wild-type metastatic colorectal cancer: Final results of a phase II open-label clinical trial ﻿

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study) ﻿

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer ﻿

Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: A retrospective analysis ﻿

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen ﻿

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers ﻿

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ?3 circulating tumour cells: the randomised phase III VISNÚ-1 trial ﻿

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study ﻿

Maintenance treatment with cetuximab in a series of patients treated with standard chemotherapy and cetuximab in metastatic colorectal cancer ﻿

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer ﻿

Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study) ﻿

Sorafenib (SOR) in advanced non-small cell lung cancer (NSCLC): A phase II study of patient progress after several lines of treatment ﻿

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of KRAS wild-type metastatic colorectal cancer: Final results of a phase II open-label clinical trial

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: A retrospective analysis

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ?3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

Maintenance treatment with cetuximab in a series of patients treated with standard chemotherapy and cetuximab in metastatic colorectal cancer

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)

Sorafenib (SOR) in advanced non-small cell lung cancer (NSCLC): A phase II study of patient progress after several lines of treatment